There’s a certain irony in building a company around chromosomal inversions and complex rearrangements, because KROMATID has made a career out of rearranging expectations in genomic analysis. On August 20, 2025, the Boulder-based biotech announced an $8 million Series C raise led by BroadOak Capital Partners, with strategic investors returning for more. Exceeding capital goals wasn’t a lucky bounce. It was execution as sharp as the assays they run, single-cell precision applied to business growth.
Founded in 2007 by Dr. Christopher Tompkins and Erin Cross, the company emerged from Colorado State University with a challenge: what critical genomic events are we missing because traditional sequencing looks at the crowd instead of the individual? Their answer became directional Genomic Hybridization, or dGH, a platform that detects inversions, translocations, and complex rearrangements at two-kilobase resolution. Instead of guessing at pooled averages, KROMATID reveals the truth hiding in rare cells. That vision has turned into more than sixty global clients, over thirty peer-reviewed papers, and a reputation for solving the problems others don’t even see.
Commercially, the company has found its stride. In the last year, assay volume more than doubled and projections show another threefold increase on deck. The KROMASURE suite, dGH SCREEN, dGH InSite, and PinPoint offers high-throughput, automation-ready workflows that scale to more than ten thousand cells per run. Add in ISO certification, GLP compliance, integration with sequencing pipelines, and a growing IP portfolio, and you have a platform designed not just for science but for market dominance in cell and gene therapy.
Leadership is built for the long game. Dr. Christopher Tompkins now leads as CEO after years driving the platform forward. Erin Cross, Vice President of Platform Development, continues to advance the technology she helped invent. Board Chair James E. Chomas brings the experience of turning patents into global businesses, while scientific advisors like Dr. Susan Bailey and Dr. Joel Bedford keep KROMATID tied to cutting-edge research with NASA, NIST, and top universities.
The $8 million Series C isn’t just runway, it’s acceleration. Funds will expand automated lab capacity, scale global sales, launch a European service hub in 2026, and deepen partnerships with pharma and biotech. With the cell and gene therapy market projected to hit $28 billion and CRISPR racing ahead at 15% CAGR, the demand for trusted genomic integrity analysis has never been higher. BroadOak Capital Partners knows the stakes, and they’re betting KROMATID isn’t just part of the market; it’s setting the standard.
